Literature DB >> 6313397

Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog.

D B Vaupel.   

Abstract

SKF 10,047, N-allylnormetazocine, a benzomorphan narcotic antagonist, and the arylcyclohexylamine anesthetic phencyclidine produced similar reflex, autonomic and behavioral effects in the chronic spinal dog which were not antagonized by naltrexone pretreatment. Naltrexone did effectively prevent the effects of morphine. These data provide further evidence that the acute effects of phencyclidine and SKF 10,047 are alike and that their principal mechanism of action does not involve opiate activity of the morphine type.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313397     DOI: 10.1016/0014-2999(83)90297-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  39 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice.

Authors:  Jiajia Wang; Aisha L Mack; Andrew Coop; Rae R Matsumoto
Journal:  Eur Neuropsychopharmacol       Date:  2007-03-21       Impact factor: 4.600

3.  Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the sigma-1 receptor.

Authors:  Arindam Pal; Uyen B Chu; Subramaniam Ramachandran; David Grawoig; Lian-Wang Guo; Abdol R Hajipour; Arnold E Ruoho
Journal:  J Biol Chem       Date:  2008-05-07       Impact factor: 5.157

4.  The sigma receptor: evolution of the concept in neuropsychopharmacology.

Authors:  T Hayashi; Tp Su
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

5.  Sigma-1 receptor mediates acquisition of alcohol drinking and seeking behavior in alcohol-preferring rats.

Authors:  Angelo Blasio; Marta Valenza; Malliga R Iyer; Kenner C Rice; Luca Steardo; T Hayashi; Pietro Cottone; Valentina Sabino
Journal:  Behav Brain Res       Date:  2015-04-04       Impact factor: 3.332

Review 6.  PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation.

Authors:  Zeinab Y Motawe; Salma S Abdelmaboud; Javier Cuevas; Jerome W Breslin
Journal:  Int J Biochem Cell Biol       Date:  2020-07-12       Impact factor: 5.085

7.  Inhibition of (+)[3H]SKF 10,047 binding to rat brain membranes by FAB fragments from a monoclonal antibody directed against the opioid receptor.

Authors:  C B Tyler; J M Bidlack
Journal:  Neurochem Res       Date:  1988-08       Impact factor: 3.996

Review 8.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  A role for sigma receptors in stimulant self-administration and addiction.

Authors:  Jonathan L Katz; Weimin C Hong; Takato Hiranita; Tsung-Ping Su
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

10.  Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine.

Authors:  B L Largent; A L Gundlach; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.